Press releases

* (R) = Regulatory press releases

Jun 17, 2025

(R) Cantargia signs SEK 50 million financing facility agreement, extending cash runway into 2026 and providing operating flexibility to drive strategic plans
Jun 11, 2025

Cantargia’s nadunolimab antibody awarded US FDA Fast Track Designation
May 19, 2025

Cantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation
May 15, 2025

(R) Bulletin from the Annual General Meeting in Cantargia AB
May 13, 2025

(R) Cantargia publishes interim report for the first quarter of 2025
May 12, 2025

Cantargia announces successful Phase 1 results: PK/PD data of subcutaneously administered CAN10 confirms every 4-week dosing choice in Phase 2
May 6, 2025

Cantargia’s announces publication of clinical data demonstrating potential of nadunolimab plus pembrolizumab in solid tumors
Apr 29, 2025

Invitation to the presentation of Cantargia’s interim report for Q1 2025
Apr 29, 2025

Cantargia announces selection of treatment resistant atopic dermatitis as second target indication for CAN10
Apr 28, 2025

Cantargia announces the publication of preclinical data highlighting nadunolimab's potential to counteract tumor-driven systemic immunosuppression
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB